-
Je něco špatně v tomto záznamu ?
Secretoneurin as a Novel Biomarker of Cardiovascular Episodes: Are We There Yet? A Narrative Review
J. Plášek, M. Lazárová, J. Dodulík, P. Šulc, D. Stejskal, Z. Švagera, F. Všianský, J. Václavík
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
Free Medical Journals od 2012
PubMed Central od 2012
Europe PubMed Central od 2012
ProQuest Central od 2019-01-01
Open Access Digital Library od 2012-01-01
Open Access Digital Library od 2012-01-01
Health & Medicine (ProQuest) od 2019-01-01
ROAD: Directory of Open Access Scholarly Resources od 2012
Odkazy
PubMed
36498765
DOI
10.3390/jcm11237191
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Secretoneurin (SN) is a 33 amino-acid evolutionary conserved neuropeptide from the chromogranin peptide family. SN's main effects may be cardioprotective and are believed to be mediated through its inhibition of calmodulin-dependent kinase II (CaMKII), which influences intracellular calcium handling. SN inhibition of CaMKII suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. This action may reduce the risk of ventricular arrhythmias and calcium-dependent remodelling in heart failure. SN is also involved in reducing the intracellular reactive oxygen species concentration, modulating the immune response, and regulating the cell cycle, including apoptosis. SN can predict mortality in different disease states, beyond the classical risk factors and markers of myocardial injury. Plasma SN levels are elevated soon after an arrhythmogenic episode. In summary, SN is a novel biomarker with potential in cardiovascular medicine, and probably beyond.
Dept of Internal Medicine and Cardiology University Hospital Ostrava 70800 Ostrava Czech Republic
Institute of Laboratory Medicine University Hospital Ostrava 70800 Ostrava Czech Republic
Institute of Laboratory Medicine University of Ostrava 70103 Ostrava Czech Republic
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22031127
- 003
- CZ-PrNML
- 005
- 20230127131039.0
- 007
- ta
- 008
- 230119s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/jcm11237191 $2 doi
- 035 __
- $a (PubMed)36498765
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Plášek, Jiří $u Dept. of Internal Medicine and Cardiology, University Hospital Ostrava, 70800 Ostrava, Czech Republic $u Research Center for Internal and Cardiovascular Diseases, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $1 https://orcid.org/0000000251839557
- 245 10
- $a Secretoneurin as a Novel Biomarker of Cardiovascular Episodes: Are We There Yet? A Narrative Review / $c J. Plášek, M. Lazárová, J. Dodulík, P. Šulc, D. Stejskal, Z. Švagera, F. Všianský, J. Václavík
- 520 9_
- $a Secretoneurin (SN) is a 33 amino-acid evolutionary conserved neuropeptide from the chromogranin peptide family. SN's main effects may be cardioprotective and are believed to be mediated through its inhibition of calmodulin-dependent kinase II (CaMKII), which influences intracellular calcium handling. SN inhibition of CaMKII suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. This action may reduce the risk of ventricular arrhythmias and calcium-dependent remodelling in heart failure. SN is also involved in reducing the intracellular reactive oxygen species concentration, modulating the immune response, and regulating the cell cycle, including apoptosis. SN can predict mortality in different disease states, beyond the classical risk factors and markers of myocardial injury. Plasma SN levels are elevated soon after an arrhythmogenic episode. In summary, SN is a novel biomarker with potential in cardiovascular medicine, and probably beyond.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Lazárová, Marie $u Dept. of Internal Medicine and Cardiology, University Hospital Ostrava, 70800 Ostrava, Czech Republic
- 700 1_
- $a Dodulík, Jozef $u Dept. of Internal Medicine and Cardiology, University Hospital Ostrava, 70800 Ostrava, Czech Republic
- 700 1_
- $a Šulc, Patrik $u Dept. of Internal Medicine and Cardiology, University Hospital Ostrava, 70800 Ostrava, Czech Republic
- 700 1_
- $a Stejskal, David $u Institute of Laboratory Medicine, University Hospital Ostrava, 70800 Ostrava, Czech Republic $u Institute of Laboratory Medicine, University of Ostrava, 70103 Ostrava, Czech Republic
- 700 1_
- $a Švagera, Zdeněk $u Institute of Laboratory Medicine, University Hospital Ostrava, 70800 Ostrava, Czech Republic $u Institute of Laboratory Medicine, University of Ostrava, 70103 Ostrava, Czech Republic
- 700 1_
- $a Všianský, František $u Institute of Laboratory Medicine, University Hospital Ostrava, 70800 Ostrava, Czech Republic
- 700 1_
- $a Václavík, Jan $u Dept. of Internal Medicine and Cardiology, University Hospital Ostrava, 70800 Ostrava, Czech Republic $u Research Center for Internal and Cardiovascular Diseases, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic
- 773 0_
- $w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 11, č. 23 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36498765 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230119 $b ABA008
- 991 __
- $a 20230127131030 $b ABA008
- 999 __
- $a ok $b bmc $g 1889375 $s 1182460
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2022 $b 11 $c 23 $e 20221203 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
- LZP __
- $a Pubmed-20230119